A lot of people exited the stock prior to earnings, knowing that the loss of CVS was going to make it a bad quarter, but I imagine there will be steady accumulation now in advance of the analysts/investors day and in anticipation that Italy will be aboard soon. Amarin's share price rise may be as drip-drip as the fall has been. By this time next year, sales in Europe and elsewhere will probably surpass U.S. sales and it will become easier then to project the growth of revenues. At that point, the company might even be ripe for a sale.
Market Data 
Markets 
AI
